Two of our experts, David Heal and Sharon Smith, have recently been editors of a Special Issue of Neuropharmacology on psychedelic drugs.
Psychedelics: New Doors, Altered Perceptions. Edited by: David J Heal, Sharon L Smith, Jack Henningfield, Bruno G. Frenguelli and David J Nutt. Neuropharmacology Volume 142, pages 1-276 (November 2018).
The Special Issue celebrates the pivotal discovery of LSD and reviews the growing evidence that psychedelic drugs could have value in treatment of a range of psychiatric conditions. This major body of work in an exciting new field contains 14 reviews by leading world experts and 6 articles on original research findings. Topics include: basic pharmacology, therapeutic evaluation in psychiatric disorders, brain imaging, drug development and abuse liability assessment. Click here for further details.
In addition to the editorial, we have contributed a review on the non-clinical assessment of the drug abuse liability of psychedelic drugs.
Please contact us to learn more about our non-clinical models for predicting the risk of abuse and/or dependence of centrally-acting compounds.